Current treatment for Ewing’s sarcoma
Authors:
- Mihir M ThackerMTMihir M Thacker
- H Thomas TempleHTH Thomas Temple
- Sean P ScullySSSean P Scully
- 1 April 2005
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 5 (2) , 319-331
Abstract
Ewing's sarcoma is the second most common primary bone tumor seen in children and adolescents, and was described by James Ewing in 1921 as a diffuse endothelioma of bone. It is one of the differential diagnoses of pediatric small round blue cell tumors. This is not a single condition, but a group of morphologically and clinically closely related disorders with similar molecular biology -- expression of tumor-specific chimeric oncoproteins through balanced chromosomal translocations involving the EWS gene -- often referred to as the Ewing family of tumors. This includes Ewing's sarcoma of bone, extra-osseous Ewing's sarcoma, Askin tumor and peripheral neuroectodermal tumor. These are aggressive neoplasms with almost 25% of patients having clinically evident metastases at presentation. Ewing's sarcoma has therefore been considered as a systemic disease necessitating local as well as systemic treatment. An aggressive multidisciplinary approach has resulted in significant improvement in prognosis for patients with these tumors. Despite aggressive treatment, 20-40% of patients with localized disease and almost 80% of patients with metastatic disease at presentation succumb to the illness. Advances in understanding the molecular biology of these tumors will hopefully result in the development of novel treatment approaches. The aim of this article is to review the existing treatment methods and to highlight the more recent approaches to the treatment of this condition.Keywords
This publication has 108 references indexed in Scilit:
- Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferationOncogene, 2003
- A systematic review of molecular and biological markers in tumours of the Ewing's sarcoma familyEuropean Journal of Cancer, 2003
- The rapamycin-sensitive signal transduction pathway as a target for cancer therapyOncogene, 2000
- EWS Fli-1 Antisense Nanocapsules Inhibits Ewing Sarcoma-Related Tumor in MiceBiochemical and Biophysical Research Communications, 2000
- Local therapy and other factors influencing site of relapse in patients with localised Ewing's sarcomaEuropean Journal of Cancer, 1999
- Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing’s sarcomaBone Marrow Transplantation, 1998
- Ewing’s sarcoma of the pelvis: changes over 25 years in treatment and resultsEuropean Journal of Cancer, 1997
- Clavicula pro Humero - eine neue Operationsmethode für maligne Tumoren des proximalen HumerusZeitschrift für Orthopädie und ihre Grenzgebiete, 1992
- Influence of Doxorubicin Dose Intensity on Response and Outcome for Patients With Osteogenic Sarcoma and Ewing's SarcomaJNCI: Journal of the National Cancer Institute, 1991
- Bone Sarcomas Linked to Radiotherapy and Chemotherapy in ChildrenNew England Journal of Medicine, 1987